Our data are in good agreement with the results of Groenewoud et al. [10] and Stancakova et al. [11], who reported that CDKAL1 variants decreased first-phase insulin secretion but not second-phase insulin in humans with type 2 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.